Company: RVRC
Filing Date: 2025-02-14
Form Type: S-1
Source: 0001213900-25-013823
Chunk: 133

Company: Revium Rx.
Filing Date: 2025-02-14
Form: S-1
Chunk 133
---
 payables totaled $72, $105, $99 and $315, respectively, is a debt to the "Yissum" company. The "Yissum" company coordinates the economic activities for the Company's research services under an exclusive license agreement signed on November 24, 2022 (refer also to Note 11).

"Yissum" owns 2.3%, 6.6%, 6.6% and 5.82% of the Company's share capital as of September 30, 2024, July 23, 2024, December 31, 2022, and 2023, respectively.

NOTE 14 – SUBSEQUENT EVENTS

| a. | On                                                                                            
 November 11, 2024, following discussions with the management of the Company, the Board has    
 determined that it is advisable and in the best interests of the Company and its stockholders 
 to further amend the Plan, as amended (“Amendment #2”), to reduce the maximum                 
 number of shares reserved for issuance under the Plan from 20,000,000 shares of Common Stock  
 to 10,000,000 shares of Common Stock. Amendment No. 2 became effective on the date of the     
 approval by the Board of Directors, but it is subject to approval by the Company’s            
 shareholders within 12 months, pursuant to section 422(b)(1) of the Internal Revenue Code.    |

| d. | On                                                                                          
 December 31, 2024, the Board approved a grant under the Company’s Global Share Incentive    
 Plan (2021) to an employee of the Predecessor of 740,000 stock options at an exercise price 
 of $0.30 per share. Of the options granted, options for 560,000 shares were fully vested    
 upon grant and the remaining 180,000 options are to be vest on April 10, 2025. The options  
 exercisable within eight years from grant date                                              |

<div align='center'>F-27

REVIUM RX. (FORMELY REVIUM RECOVERY, INC.)

CONSOLIDATED FINANCIAL STATEMENTS

AS OF DECEMBER 31, 2023

U.S. DOLLARS IN THOUSANDS

INDEX</div>

|                                                         |     | Page        |
| Report of Independent Registered Public Accounting Firm |     | F-29        |
| Consolidated Balance Sheets                             |     | F-30        |
| Consolid